timothy sykes logo
MRNA Stock Jumps As Flu Win And Expansion Fuel Momentum Thumbnail
G Google News

MRNA Stock Jumps As Flu Win And Expansion Fuel Momentum

BRYCE TUOHEY•UPDATED JUN. 23, 2026, 11:33 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 4.52 percent after promising clinical trial data strengthened confidence in its pipeline.

Key Takeaways For MRNA Traders

  • An FDA advisory committee (VRBPAC) voted unanimously (9-0) that Moderna’s investigational flu vaccine mRNA-1010/mFLUSIVA has a favorable benefit–risk profile for adults 50–64 and 65+, backing its Biologics License Application ahead of an 2026/08/05 PDUFA decision.
  • Moderna is restructuring its operating model and leadership to transition from a single-product COVID vaccine company to a diversified biotechnology business built around three commercial franchises and multiple potential vaccine, oncology, and rare disease launches starting in 2027–2028.
  • Moderna plans to invest in German production sites and is interested in acquiring facilities that BioNTech intends to close, a move that sent MRNA shares up roughly 8–12% and signals an expansion of its European manufacturing footprint.
  • Jefferies reiterated a Hold rating and $45 price target on Moderna after the unanimous FDA advisory vote on mFLUSIVA, seeing increased confidence in eventual approval but expecting meaningful flu revenues only from around 2027 and U.S. flu plus flu/COVID combo sales of about $750M by 2030.
  • Moderna scheduled a 2026/06/25 Investor Science Day to showcase its research and early development pipeline, emphasizing how its mRNA platform, combined with AI and robotics, is accelerating innovation and enabling expansion into new therapeutic areas.

Candlestick Chart

Live Update At 11:32:21 EDT: On Tuesday, June 23, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 4.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, the recent tape on MRNA tells the story better than any pitch deck. Over the last few weeks, Moderna stock has pushed from the mid-$40s to the low $60s, with the latest close near $62.03 after an intraday range between $58.34 and $63.98. That is a sharp rebound from the 2026/06/02 low around the mid-$40s and reflects how quickly sentiment can flip when catalysts line up.

Intraday, MRNA showed steady buying pressure. After opening just under $59, the stock climbed into the low $60s, held most gains, and traded in a tight $61.50–$63.50 band through late morning. That kind of consolidation after a spike often signals strong hands stepping in, not just a one-and-done headline pop.

More Breaking News

Fundamentally, the story is still early-stage biotech math. Moderna generated about $1.94B in revenue over the last period but is running very negative margins, with EBIT margin near -140% and profit margin around -143%. The latest quarter showed revenue of $389M against a net loss of roughly $1.34B and free cash flow of about -$692M. On the plus side, MRNA has a solid balance sheet, with roughly $5.21B in cash and short-term investments, low debt (total debt-to-equity around 0.17), and a current ratio of 2.4. For traders, that cash cushion buys time for the mRNA pipeline to mature even as the income statement bleeds.

Why Traders Are Watching MRNA Now

MRNA is back on momentum screens because the news flow finally lines up with the chart. The big catalyst: an FDA advisory committee voted 9–0 that Moderna’s mRNA-1010 seasonal flu vaccine, branded as mFLUSIVA, has a favorable benefit–risk profile in adults 50–64 and 65+. FDA advisers also backed full approval for 50–64 and accelerated approval for 65+, pushing MRNA up roughly 4% intraday around the panel.

For traders, a unanimous panel is exactly what you want to see. It sharply increases the odds of full approval by the 2026/08/05 PDUFA date and sets the stage for MRNA to move beyond being a one-product COVID story. This is a clean, binary de‑risking event. The FDA briefing documents ahead of the 2026/06/18 meeting were described as “balanced and not harsh,” which helped remove downside risk before the vote.

At the same time, the stock isn’t trading like a pure hype machine. Jefferies kept a Hold rating and a $45 target, stressing that real flu money probably starts around 2027, with U.S. flu plus flu/COVID combo sales seen at about $750M by 2030. That gap between the bullish tape and cautious models is where short-term traders live.

The strategy reset is adding fuel. Moderna announced a restructuring to support three commercial franchises and a broader mRNA pipeline across vaccines, oncology, and rare diseases for 2027–2028 launches. The market liked it: MRNA jumped about 6.3% and became the second‑best S&P 500 name on that day. On top of that, MRNA surged 8–12% after news it wants to invest in German production sites and may pick up plants BioNTech plans to close, expanding European capacity at what could be distressed prices.

Layer in UK approval for an early cancer vaccine trial for Lynch syndrome and BARDA-linked work on Bundibugyo ebolavirus, and you get a picture of Moderna as a platform, not a single shot. For active trading, that means multiple upcoming catalysts — regulatory decisions, trial updates, the 2026/06/25 Investor Science Day — that can trigger sharp moves.

Conclusion

Right now, MRNA is a classic momentum-plus-catalyst setup. The stock has broken out from the $40s into the $60s on real news: a unanimous FDA panel endorsement for mFLUSIVA, a visible path to a second commercial product, a retooled operating model, and an aggressive manufacturing expansion into Germany. The balance sheet shows Moderna has the cash to keep swinging, even while earnings stay deep in the red.

At the same time, Wall Street models are still conservative. With meaningful flu revenues not expected until around 2027 and combo flu/COVID sales projected at about $750M by 2030, the fundamental payoff is a few years out. That tension — hot near-term headlines versus long-dated cash flows — is exactly what makes MRNA attractive for educated trading, not for anyone looking for guarantees.

For traders in the Tim Sykes community, the playbook is familiar: respect the trend, but never marry the stock. MRNA has clear catalyst dates, a volatile chart, and a crowd that reacts fast to every FDA and pipeline headline. As Tim Sykes always says, “Patterns repeat, but you have to be prepared.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With Moderna, the pattern right now is momentum fueled by real regulatory wins — and disciplined traders will treat every spike and pullback as data, not destiny.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”